Prognostic Significance of Preoperative NLR or PLR and PASS Score Combinations in Pheochromocytoma and Paraganglioma

IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ümit Çavdar, Derya Sema Yaman Kalender, Berna Demir Yüksel, Barış Önder Pamuk, Abdurrahman Çömlekçi, Mehmet Sercan Ertürk, Emine Özlem Gür, Aslı Kahraman, Kutsal Yörükoglu, Serkan Yener
{"title":"Prognostic Significance of Preoperative NLR or PLR and PASS Score Combinations in Pheochromocytoma and Paraganglioma","authors":"Ümit Çavdar,&nbsp;Derya Sema Yaman Kalender,&nbsp;Berna Demir Yüksel,&nbsp;Barış Önder Pamuk,&nbsp;Abdurrahman Çömlekçi,&nbsp;Mehmet Sercan Ertürk,&nbsp;Emine Özlem Gür,&nbsp;Aslı Kahraman,&nbsp;Kutsal Yörükoglu,&nbsp;Serkan Yener","doi":"10.1111/cen.15192","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Context</h3>\n \n <p>Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have recently emerged in assessing pheochromocytomas and paragangliomas (PPGLs). However, their combined use with PASS scale has not yet been explored.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Our goal was to investigate the prognostic values of NLR and PLR and incorporate the PASS score into our analysis.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Data from 74 histologically confirmed pheochromocytomas/paragangliomas across two centres were assessed. Poor prognosis was characterised by the presence of metastasis or disease-specific mortality. Clinical characteristics such as age, gender, primary tumour size and location, and urinary metanephrine and normetanephrine levels, alongside NLR, PLR, and the PASS score as prognostic markers, were analysed. The prognostic value of the PASS score combined with NLR or PLR was evaluated using Receiver Operating Characteristic Curve (ROC), univariate, and multivariate regression analyses.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Sixty-four patients with better prognosis and 10 patients with poor prognosis were included in the analysis, with mean PASS scores of 4 and 9, respectively. Poor prognosis was significantly higher in patients with NLR Á 3.43 (Area Under Curve(AUC) = 0.761; 70% sensitivity, 82.8% specificity, 38.9% PPV and 94.7% NPV) and with PLR &gt; 193.12 (AUC = 0.738; 70% sensitivity, 76.2% specificity, 30% PPV and 94% NPV). The PASS and preoperative NLR or PLR combination predicted poor prognosis significantly in the multivariate models (OR: 125; 95% CI: 6.25–∞; <i>p</i> = 0.001 for PASS ≥ 6 and NLR &gt; 3.43 and OR: 28.57; 95% CI: 3–250; <i>p</i> = 0.003 for PASS ≥ 6 and PLR &gt; 193.12).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>As the roles of NLR and PLR in prediction of prognosis is gaining recognition, combining these with PASS score may improve preoperative stratification of prognosis and management of patients.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":"102 3","pages":"362-368"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15192","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Context

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have recently emerged in assessing pheochromocytomas and paragangliomas (PPGLs). However, their combined use with PASS scale has not yet been explored.

Objective

Our goal was to investigate the prognostic values of NLR and PLR and incorporate the PASS score into our analysis.

Methods

Data from 74 histologically confirmed pheochromocytomas/paragangliomas across two centres were assessed. Poor prognosis was characterised by the presence of metastasis or disease-specific mortality. Clinical characteristics such as age, gender, primary tumour size and location, and urinary metanephrine and normetanephrine levels, alongside NLR, PLR, and the PASS score as prognostic markers, were analysed. The prognostic value of the PASS score combined with NLR or PLR was evaluated using Receiver Operating Characteristic Curve (ROC), univariate, and multivariate regression analyses.

Results

Sixty-four patients with better prognosis and 10 patients with poor prognosis were included in the analysis, with mean PASS scores of 4 and 9, respectively. Poor prognosis was significantly higher in patients with NLR Á 3.43 (Area Under Curve(AUC) = 0.761; 70% sensitivity, 82.8% specificity, 38.9% PPV and 94.7% NPV) and with PLR > 193.12 (AUC = 0.738; 70% sensitivity, 76.2% specificity, 30% PPV and 94% NPV). The PASS and preoperative NLR or PLR combination predicted poor prognosis significantly in the multivariate models (OR: 125; 95% CI: 6.25–∞; p = 0.001 for PASS ≥ 6 and NLR > 3.43 and OR: 28.57; 95% CI: 3–250; p = 0.003 for PASS ≥ 6 and PLR > 193.12).

Conclusion

As the roles of NLR and PLR in prediction of prognosis is gaining recognition, combining these with PASS score may improve preoperative stratification of prognosis and management of patients.

嗜铬细胞瘤和副神经节瘤术前NLR或PLR及PASS评分组合的预后意义。
背景:中性粒细胞与淋巴细胞比率(NLR)和血小板与淋巴细胞比率(PLR)最近被用于评估嗜铬细胞瘤和副神经节瘤(PPGLs)。然而,它们与PASS量表的结合使用尚未进行探索。目的:我们的目的是探讨NLR和PLR的预后价值,并将PASS评分纳入我们的分析。方法:对来自两个中心的74例经组织学证实的嗜铬细胞瘤/副神经节瘤的数据进行评估。预后不良的特点是存在转移或疾病特异性死亡率。分析临床特征,如年龄、性别、原发肿瘤大小和位置、尿中肾上腺素和去甲肾上腺素水平,以及NLR、PLR和PASS评分作为预后指标。采用受试者工作特征曲线(ROC)、单因素和多因素回归分析评估PASS评分联合NLR或PLR的预后价值。结果:纳入预后较好患者64例,预后较差患者10例,平均PASS评分分别为4分和9分。NLR患者的不良预后显著高于Á 3.43(曲线下面积(AUC) = 0.761;敏感性为70%,特异性为82.8%,PPV为38.9%,NPV为94.7%),PLR为193.12 (AUC = 0.738;敏感性70%,特异性76.2%,PPV 30%, NPV 94%)。在多变量模型中,PASS和术前NLR或PLR联合预测预后不良(or: 125;95% ci: 6.25-∞;PASS≥6时p = 0.001, NLR为3.43,OR为28.57;95% ci: 3-250;PASS≥6时p = 0.003, PLR为193.12)。结论:随着NLR和PLR在预测预后中的作用逐渐得到认可,将其与PASS评分相结合可以改善患者术前的预后分层和管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Endocrinology
Clinical Endocrinology 医学-内分泌学与代谢
CiteScore
6.40
自引率
3.10%
发文量
192
审稿时长
1 months
期刊介绍: Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信